SCHEMBL13412908

SCHEMBL13412908

COc1cc(CC(=O)O)ccc1OCC1CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.54
THRB P10828 1/20 0.54
CA5A P35218 1/20 0.53
GAA P10253 3/20 0.52
ALDH1A1 P00352 1/20 0.52
TSHR P16473 1/20 0.52
NFKB1 P19838 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
PARP15 Q460N3 1/20 0.50
PARP10 Q53GL7 1/20 0.50
ELANE P08246 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48
PTGDR2 Q9Y5Y4 3/20 0.47
EPHX1 P07099 1/20 0.46
SELL P14151 1/20 0.46
SELP P16109 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3054967 0.96 CA5A (0.54) THRATHRBCA5AGAAALDH1A1
SCHEMBL31661761 0.96 CA5A (0.54) THRATHRBCA5AGAAALDH1A1
SCHEMBL13412905 0.93 CA5A (0.57) CA5AGAAALDH1A1TSHRNFKB1
SCHEMBL17026725 0.89 ALDH1A1 (0.54) THRATHRBALDH1A1KMT2APTGDR2
SCHEMBL17026727 0.82 ALDH1A1 (0.54) THRATHRBCA5AGAAALDH1A1
SCHEMBL7792682 0.80 PTGDR2 (0.57) CA5AGAAALDH1A1TSHRNFKB1
SCHEMBL31661693 0.80 RECQL (0.58) THRATHRBCA5AGAAALDH1A1
SCHEMBL6366618 0.80 RECQL (0.58) THRATHRBCA5AGAAALDH1A1
SCHEMBL30049382 0.79 GAA (0.74) CA5AGAAALDH1A1TSHRNFKB1
SCHEMBL153055 0.79 GAA (0.74) CA5AGAAALDH1A1TSHRNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO claimed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US claimed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO disclosed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US disclosed
EP-2129218-B1 COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2016-10-19 EP disclosed
US-8383852-B2 Compounds having a cyclic moiety and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2013-02-26 US disclosed
US-8383852-B2 Compounds having a cyclic moiety and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2013-02-26 US disclosed
US-20100074861-A1 COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2010-03-25 US disclosed
US-20100074861-A1 COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2010-03-25 US disclosed
WO-2008101240-A1 COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100074861-A1 COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS PAICS, ABCB4, ALPP THRA 3597/4885THRB 2855/4885CA5A 300/4885
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS SI, SLC20A1, SLC20A2 THRA 4819/4885THRB 4719/4885CA5A 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.